This prospective, single arm, multi-center pilot study includes 120 mRCC patients over 65
years, no prior systemic treatment, determined to be candidates for systemic therapy by the
investigator. The treatment with Sorafenib should comply with the recommendations written in
the local product information. The primary endpoint is overall survival. The secondary
endpoints including other effectiveness points, safety and patients characteristics. With 120
completed patients, if the observed survival rate at 12 months is 60%, the width of a 95%
confidence interval will be approximately 18%.